Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma
European Journal of Cancer · 2026-06 · 242 · 116808
DOI: 10.1016/j.ejca.2026.116808 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Yoshiko Hashii und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, the University of Osaka Graduate School of Medicine, Suita, Japan. Electronic address: yoshiko.hashii@oici.jp. Hauptthemen laut MEDLINE: WT1 Proteins, Brain Stem Neoplasms, Diffuse Intrinsic Pontine Glioma, Cancer Vaccines. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Sumitomo Pharma Co Ltd.
Abstract (Originalsprache)
BACKGROUND: The prognosis of pediatric patients with diffuse intrinsic pontine glioma (DIPG), glioblastoma, or anaplastic astrocytomas (AAs) is dismal. This first-in-child phase 1/2 study examined the safety and efficacy of a Wilms' tumor gene 1 (WT1) peptide vaccine, along with the associations of delayed-type hypersensitivity (DTH) and cytotoxic T lymphocyte (CTL) frequency/count with clinical outcomes. METHODS: Patients (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, the University of Osaka Graduate School of Medicine, Suita, Japan. Electronic address: yoshiko.hashii@oici.jp.
- Department of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka, Japan.
- Division of Neuro-Oncology, Children's Cancer Center, National Center for Child Health and Development, Setagaya-ku, Japan.
- Division of Hematology/Oncology, Kanagawa Children's Medical Center Childhood Cancer Center, Yokohama, Japan.
- Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
- Department of Clinical Oncology & Neuro-oncology Program, Hiroshima University Hospital, Hiroshima, Japan.
Förderung
- Sumitomo Pharma Co Ltd
Zitieren
APA
Hashii, Y., Fujisaki, H., Terashima, K., Goto, H., Horibe, K., Sugiyama, K., Takahara-Matsubara, M., Goto, M., Yanagisawa, T., Kikuta, A., Kawamoto, H., Hashimoto, N., Oka, Y., Sugiyama, H., & Hara, J. (2026). Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma. European Journal of Cancer, 242, 116808. https://doi.org/10.1016/j.ejca.2026.116808
Vancouver
Hashii Y, Fujisaki H, Terashima K, Goto H, Horibe K, Sugiyama K, et al. Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma. European Journal of Cancer. 2026;242:116808. doi:10.1016/j.ejca.2026.116808
BibTeX
@article{Hashii2026,
author = {Hashii, Yoshiko and Fujisaki, Hiroyuki and Terashima, Keita and Goto, Hiroaki and Horibe, Keizo and Sugiyama, Kazuhiko and Takahara-Matsubara, Mariko and Goto, Masashi and Yanagisawa, Takaaki and Kikuta, Atsushi and Kawamoto, Hiroshi and Hashimoto, Naoya and Oka, Yoshihiro and Sugiyama, Haruo and Hara, Junichi},
title = {Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma},
journal = {European Journal of Cancer},
year = {2026},
volume = {242},
pages = {116808},
doi = {10.1016/j.ejca.2026.116808}
}
EUVIMED